BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 9, 2017
View Archived Issues
Ono reviews developments of second quarter of fiscal 2017
Read More
Sanofi presents key product and pipeline events of third quarter 2017
Read More
FDA clears Sarepta Therapeutics' IND for DMD candidate
Read More
OncoResponse completes acquisition of Paganini Biopharma
Read More
NX-AS-401 enhances the antibiotic effect of tobramycin in vitro and in vivo
Read More
FDA grants RMAT designation to Cellvation's CEVA-101
Read More
Invirsa closes seed financing to develop INV-102
Read More
Synlogic's SYNB-1020 demonstrates safety and tolerability in phase I study
Read More
CRISPR/Cas technology used to target HPV oncoprotein E6 for cervical cancer
Read More
Long-lasting enhancement of cognitive capabilities using AAV vector expressing the Klotho gene
Read More
Nightstar Therapeutics licenses gene therapy for Stargardt disease
Read More
Sosei gains Japanese license to HTL-0018318 for dementia with Lewy bodies under Allergan partnership
Read More
Torrent Pharmaceuticals discloses novel PI3K inhibitors
Read More
Boehringer Ingelheim initiates first-in-human study of BI-894416
Read More
ApoGlyx divulges new AQP9 inhibitors
Read More
Millendo Therapeutics reports topline phase II results on ATR-101, discontinues MLE-4901
Read More
AstraZeneca conducts phase I trial of MEDI-1341
Read More
Novartis reports topline results from MONALEESA-7 study of Kisqali
Read More
Viiv conducts first-in-human study of maturation inhibitor GSK-3640254
Read More
Bristol-Myers Squibb identifies Nav1.7 channel blockers
Read More
Synermore compares safety and pharmacokinetics of SYN-060 to Humira
Read More
Samumed presents DYRK1A, GSK-3beta and IL-6 production inhibitors
Read More
Trial data reported for dabrafenib/trametinib/navitoclax in BRAF-mutant solid tumor patients
Read More
Rexahn Pharmaceuticals doses first patient in phase IIa study of RX-3117 plus Abraxane
Read More
HSP 90 inhibitors presented by Duke University
Read More
Novita initiates phase I study of NP-G2-044 in advanced or metastatic solid tumors
Read More
FDA approves Prevymis for CMV prevention in adult HSCT recipients
Read More
Neurimmune collaborates with Ono on discovery of antibodies for neurodegenerative diseases
Read More